News25/Ratings2
News · 26 weeks36+33%
2025-10-262026-04-19
Mix1690d
- Insider8(50%)
- SEC Filings4(25%)
- Earnings2(13%)
- Other2(13%)
Latest news
25 items- INSIDERSEC Form 4 filed by Opaleye Management Inc.4 - SANUWAVE Health, Inc. (0001417663) (Issuer)
- SECSANUWAVE Health Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits8-K - SANUWAVE Health, Inc. (0001417663) (Filer)
- PRSanuwave Health Reports Preliminary Q1 2026 Revenue of $9.6–$9.7 Million, Up 3-4% Year-over-YearSanuwave is pleased to announce preliminary revenues of $9.6 million to $9.7 million for the first quarter ended March 31, 2026, in line with prior guidance for Q1. EDEN PRAIRIE, Minn., April 16, 2026 (GLOBE NEWSWIRE) -- Sanuwave Health, Inc. (the "Company" or "Sanuwave") (NASDAQ:SNWV), a leading provider of FDA-approved directed energy systems used in advanced wound care, today announced that revenues for the first quarter of 2026 are expected to be in the range of $9.6 to $9.7 million, an increase of 3-4% over Q1 2025. This number is within the range of guidance given in the Company's Q4 2025 earnings release issued on March 26, 2026. "At the end of Q1 the Company saw several good-size
- INSIDERSEC Form 4 filed by Tyler James4 - SANUWAVE Health, Inc. (0001417663) (Issuer)
- INSIDERSEC Form 4 filed by Frank Morgan C.4 - SANUWAVE Health, Inc. (0001417663) (Issuer)
- INSIDERSEC Form 4 filed by Blizard Jeffrey4 - SANUWAVE Health, Inc. (0001417663) (Issuer)
- INSIDERSEC Form 4 filed by Bazar Gregory Matthew4 - SANUWAVE Health, Inc. (0001417663) (Issuer)
- INSIDERSEC Form 4 filed by Miller Ian D.4 - SANUWAVE Health, Inc. (0001417663) (Issuer)
- SECAmendment: SEC Form SCHEDULE 13G/A filed by SANUWAVE Health Inc.SCHEDULE 13G/A - SANUWAVE Health, Inc. (0001417663) (Subject)
- SECSANUWAVE Health Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits8-K - SANUWAVE Health, Inc. (0001417663) (Filer)
- PRSanuwave Announces Record Revenues and Financial Results for Q4 and Full Year 2025Q4 2025 revenues were $13.4 million, up 29.7% from Q4 2024. This was an all-time quarterly record for the Company. Full year 2025 revenues were $44.1 million up 35.0% from full year 2024 revenues. This was an all-time annual record for the Company. Q4 2025 gross margin was 74.7%, versus 77.9% in Q4 2024 and 77.6% in Q3 2025. Full year 2025 gross margin was 77.1% versus 75.2% in 2024. GAAP Operating Income was $2.0 million for Q4 2025 and $4.9 million for full year 2025. Company provides guidance for revenues of $9.6-10.3 million (an increase of 3-10%) for Q1 2026 as compared to Q1 2025 and initiates full year 2026 revenue guidance of 16-25% growth vs 2025 ($51.0-55.0 million). EDEN
- SECSEC Form 10-K filed by SANUWAVE Health Inc.10-K - SANUWAVE Health, Inc. (0001417663) (Filer)
- PRSanuwave Will Host a Conference Call on March 27, 2026 at 8:30 AM (ET) to Present Q4 and Full Year 2025 Financial ResultsEDEN PRAIRIE, Minn., March 20, 2026 (GLOBE NEWSWIRE) -- Sanuwave Health, Inc. (the "Company" or "Sanuwave") (NASDAQ:SNWV), a leading provider of next-generation FDA-approved wound care products, will host a live conference call on Friday, March 27, 2026, at 8:30 AM (ET) to present its Q4 and Full Year 2025 financial results. Telephone access to the call will be available by dialing the following numbers: Participant Dial-in Information Toll Free: 1-800-343-4136 Toll/International: 1-203-518-9843 Conference ID: SANUWAVE OR click the link for instant telephone access to the event:https://viavid.webcasts.com/starthere.jsp?ei=1753775&tp_key=6ca0a4cd2b Materials for the conference call
- SECSANUWAVE Health Inc. filed SEC Form 8-K: Non-Reliance on Previously Issued Financial Statements or a Related Audit Report or Completed Interim Review8-K - SANUWAVE Health, Inc. (0001417663) (Filer)
- INSIDERSEC Form 4 filed by Exec VP of Sales Wern David Timothy4 - SANUWAVE Health, Inc. (0001417663) (Issuer)
- INSIDERSEC Form 4 filed by Chief Executive Officer Frank Morgan C.4 - SANUWAVE Health, Inc. (0001417663) (Issuer)
- SECAmendment: SANUWAVE Health Inc. filed SEC Form 8-K: Submission of Matters to a Vote of Security Holders8-K/A - SANUWAVE Health, Inc. (0001417663) (Filer)
- PRSanuwave Health Announces Preliminary Q4 2025 Revenue of $13.3–$13.4 Million, Up 29–30% Year-over-Year; Achieves Record Quarterly and Full-Year RevenueSanuwave is pleased to announce preliminary revenues of $13.3 million to $13.4 million for the fourth quarter ended December 31, 2025. This represents the highest quarterly revenues in Company history. Q4 2025 revenue increased between 29% and 30% compared to Q4 2024. Full Year 2025 revenue increased to $44.3-$44.4 million up 36% vs Full Year 2024. 2025 annual revenues were an all-time record for the Company. EDEN PRAIRIE, Minn., Jan. 09, 2026 (GLOBE NEWSWIRE) -- Sanuwave Health, Inc. (the "Company" or "Sanuwave") (NASDAQ:SNWV), a leading provider of FDA-approved directed energy systems used in advanced wound care, today announced that revenues for the fourth quarter of 2025 are expecte
- INSIDERSEC Form 4 filed by Chief Executive Officer Frank Morgan C.4 - SANUWAVE Health, Inc. (0001417663) (Issuer)
- INSIDERSEC Form 4 filed by Director Miller Ian D.4 - SANUWAVE Health, Inc. (0001417663) (Issuer)
- INSIDERSEC Form 4 filed by Director Tyler James4 - SANUWAVE Health, Inc. (0001417663) (Issuer)
- INSIDERSEC Form 4 filed by Director Bazar Gregory Matthew4 - SANUWAVE Health, Inc. (0001417663) (Issuer)
- INSIDERSEC Form 4 filed by Director Blizard Jeffrey4 - SANUWAVE Health, Inc. (0001417663) (Issuer)
- SECAmendment: SEC Form SCHEDULE 13D/A filed by SANUWAVE Health Inc.SCHEDULE 13D/A - SANUWAVE Health, Inc. (0001417663) (Subject)
- INSIDERDirector by Deputization Manchester Management Co Llc sold $559,066 worth of shares (20,000 units at $27.95) (SEC Form 4)4 - SANUWAVE Health, Inc. (0001417663) (Issuer)